Dermapharm Holding SE's Strategy Proves Resilient with Strong Organic Growth in Core Markets

• Dermapharm Holding SE reported strong organic growth in its core markets, offsetting a projected decline in vaccine production.
• The company's consolidated revenue fell by 6.4% year on year to EUR 298.7 million, with adjusted EBITDA declining by 16.2% to EUR 88.7 million in Q1 2024.
• Despite the decline, the Board of Management confirmed its outlook for 2024, expecting consolidated revenue of EUR 1,170–1,210 million and adjusted EBITDA of EUR 305–315 million.
• The "Branded pharmaceuticals" segment recorded strong organic growth, largely compensating for the decline in vaccine revenue.
• The "Other healthcare products" segment saw a slight decline in revenue due to economic downturn and decreased consumption in France, Arkopharma's largest sales market.
• Revenue in the "Parallel import business" segment fell by 10.7% to EUR 56.6 million due to below-average product availability at the end of 2023/beginning of 2024.

The next important date, Dermapharm Holding SE - Publication of Quarterly Report (Cut-off date Q1), at Dermapharm Holding is on 15.05.2024.

The price of Dermapharm Holding at the time of the news was 35,68EUR and did not change compared to the previous day.
19 minutes after the article was published, the price was 35,30EUR this corresponds to a minus of -1,05 % since publication.
At this time, the index SDAX was at 15.073,21PKT (+1,35 %).

Dermapharm Holding

+0,55 %

-2,65 %

+16,88 %

-0,16 %

-21,58 %

-47,87 %

+15,41 %

+39,54 %

+39,54 %

ISIN:DE000A2GS5D8WKN:A2GS5D

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• 5J
• 10J
• Max